DK3656869T4 - Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering - Google Patents

Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering Download PDF

Info

Publication number
DK3656869T4
DK3656869T4 DK19198976.3T DK19198976T DK3656869T4 DK 3656869 T4 DK3656869 T4 DK 3656869T4 DK 19198976 T DK19198976 T DK 19198976T DK 3656869 T4 DK3656869 T4 DK 3656869T4
Authority
DK
Denmark
Prior art keywords
stem cell
modulation
combination
targeting agent
cell transplantation
Prior art date
Application number
DK19198976.3T
Other languages
English (en)
Other versions
DK3656869T3 (da
Inventor
Judith A Shizuru
Kipp Andrew Weiskopf
Aaron Michael Ring
Akanksha Chhabra
Peter Schnorr
Irving L Weissman
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55400510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3656869(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of DK3656869T3 publication Critical patent/DK3656869T3/da
Application granted granted Critical
Publication of DK3656869T4 publication Critical patent/DK3656869T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
DK19198976.3T 2014-08-26 2015-08-26 Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering DK3656869T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462041989P 2014-08-26 2014-08-26
EP15835482.9A EP3186395B2 (en) 2014-08-26 2015-08-26 Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling

Publications (2)

Publication Number Publication Date
DK3656869T3 DK3656869T3 (da) 2021-01-04
DK3656869T4 true DK3656869T4 (da) 2025-05-19

Family

ID=55400510

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19198976.3T DK3656869T4 (da) 2014-08-26 2015-08-26 Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering
DK15835482.9T DK3186395T4 (da) 2014-08-26 2015-08-26 Transplantation af stamceller med en kombination af et middel der målretter stamceller og modulation af immunoregulatorisk signalering

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15835482.9T DK3186395T4 (da) 2014-08-26 2015-08-26 Transplantation af stamceller med en kombination af et middel der målretter stamceller og modulation af immunoregulatorisk signalering

Country Status (14)

Country Link
US (4) US10406179B2 (da)
EP (4) EP3186395B2 (da)
CA (2) CA2958884C (da)
CY (1) CY1123730T1 (da)
DK (2) DK3656869T4 (da)
ES (3) ES2845898T5 (da)
FI (2) FI3186395T4 (da)
HR (1) HRP20210057T4 (da)
HU (2) HUE046387T2 (da)
LT (1) LT3656869T (da)
PL (2) PL3656869T5 (da)
PT (2) PT3186395T (da)
SI (1) SI3656869T2 (da)
WO (1) WO2016033201A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6460796B2 (ja) * 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
DK3656869T4 (da) 2014-08-26 2025-05-19 Univ Leland Stanford Junior Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering
WO2016065245A1 (en) * 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
WO2016164502A1 (en) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
ES2894335T5 (es) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
MX2018015684A (es) 2016-06-17 2019-08-29 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de celulas cd117.
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
BR112019015342A2 (pt) 2017-01-30 2020-03-10 The Board Of Trustees Of The Leland Stanford Junior University Regime de condicionamento não genotóxico para o transplante de células-tronco
CA3055957A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
WO2019084240A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF TREATING CANCER USING RADIO-labeled CD45 ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELLULAR THERAPIES
US11642379B2 (en) * 2017-12-08 2023-05-09 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment
EP3768314A4 (en) 2018-03-21 2022-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
EP3801635A4 (en) * 2018-06-07 2022-04-06 Magenta Therapeutics, Inc. THERAPEUTIC METHODS USING ANTIBODY-DRUG CONJUGATES (ADCS)
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019386976B2 (en) 2018-11-26 2024-05-30 Forty Seven, LLC Humanized antibodies against c-Kit
CA3120570A1 (en) 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
US20220211885A1 (en) * 2019-04-25 2022-07-07 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
AU2020283811A1 (en) * 2019-05-24 2021-12-16 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and CD47
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
CN114845710A (zh) 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
WO2022099083A1 (en) * 2020-11-06 2022-05-12 Bluebird Bio, Inc. Methods
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
US20250171536A1 (en) * 2022-03-01 2025-05-29 CSL Innovation Pty Ltd Methods of Bone Marrow Conditioning
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023183555A1 (en) * 2022-03-25 2023-09-28 Memorial Sloan-Kettering Cancer Center Method of promoting thymic recovery by administering hematopoietic stem cells with low c-kit expression
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
CN1254376A (zh) 1996-10-01 2000-05-24 杰龙公司 端粒酶逆转录酶
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
WO2004002425A2 (en) 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
ATE474460T1 (de) * 2002-12-13 2010-08-15 Genetix Pharmaceuticals Inc Therapeutische retrovirus-vektoren für gentherapie
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
PT3255061T (pt) * 2006-11-03 2021-07-26 Univ Leland Stanford Junior Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto
PT2242512T (pt) 2008-01-15 2016-07-18 Univ Leland Stanford Junior Métodos para manipular a fagocitose mediada por cd47
US8758750B2 (en) * 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
EP4349868A3 (en) 2010-05-14 2024-08-28 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
JP6460796B2 (ja) * 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
DK3656869T4 (da) 2014-08-26 2025-05-19 Univ Leland Stanford Junior Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY

Also Published As

Publication number Publication date
DK3656869T3 (da) 2021-01-04
FI3656869T4 (fi) 2025-06-04
US11419897B2 (en) 2022-08-23
DK3186395T4 (da) 2023-05-08
EP3656869A1 (en) 2020-05-27
US10406179B2 (en) 2019-09-10
PL3186395T3 (pl) 2020-02-28
FI3186395T4 (fi) 2023-05-25
SI3656869T1 (sl) 2021-03-31
CA2958884C (en) 2024-02-27
ES2763248T3 (es) 2020-05-27
EP3656869B1 (en) 2020-11-11
HUE046387T2 (hu) 2020-03-30
EP4257145A2 (en) 2023-10-11
HRP20210057T4 (hr) 2025-07-18
EP3656869B2 (en) 2025-04-09
PL3186395T5 (pl) 2023-06-12
EP3186395A4 (en) 2018-03-21
US20200129557A1 (en) 2020-04-30
HUE052725T2 (hu) 2021-05-28
PT3656869T (pt) 2021-01-13
EP3186395B1 (en) 2019-09-25
WO2016033201A1 (en) 2016-03-03
ES2845898T5 (en) 2025-06-17
EP3822364B1 (en) 2023-05-10
SI3656869T2 (sl) 2025-06-30
US12233093B2 (en) 2025-02-25
CY1123730T1 (el) 2022-05-27
CA2958884A1 (en) 2016-03-03
ES2845898T3 (es) 2021-07-28
US20250249042A1 (en) 2025-08-07
ES2945588T3 (es) 2023-07-04
EP4257145A3 (en) 2023-10-18
EP3822364A1 (en) 2021-05-19
PT3186395T (pt) 2019-11-20
HRP20210057T1 (hr) 2021-03-05
PL3656869T3 (pl) 2021-05-17
EP4257145B1 (en) 2025-06-25
LT3656869T (lt) 2021-01-25
US20220347224A1 (en) 2022-11-03
EP3186395A1 (en) 2017-07-05
EP3186395B2 (en) 2023-03-29
DK3186395T3 (da) 2019-11-25
CA3229961A1 (en) 2016-03-03
ES2763248T5 (es) 2023-06-22
EP3656869A8 (en) 2020-06-10
PL3656869T5 (pl) 2025-06-09
US20170224737A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
DK3656869T3 (da) Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering
IL261621A (en) Genome edited immune effector cells
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3129366T3 (da) Carbazol-indeholdende amider, carbamater og urinstoffer som kryptokrommodulatorer
DK3313747T3 (da) Samling til lukning af en flaske, tilhørende flaske og samlingsfremgangsmåde
DK3134151T3 (da) Sprøjte med rullemembran
EP3183346C0 (en) CHANNEL MODULATORS
DK3220909T3 (da) Bupropion til modulation af lægemiddelplasmaniveauer af dextrometorphan
DK3221306T3 (da) Heteroarylforbindelser som irak-inhibitorer og anvendelser deraf
DK3597742T3 (da) Car-udtrykkende vektor og car-udtrykkende t-celler
DK3524680T3 (da) Sammensætninger og fremgangsmåder til modulation af ttr-ekspression
DK3628680T3 (da) Modulering af komplementaktivitet
DK3198348T3 (da) Generering af en styresekvens til kvantestyring
DK3125927T3 (da) Fremgangsmåder og sammensætninger til immunmodulering
DK3142858T3 (da) Åndbar og mikroporøs, tynd termoplastfilm
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
DK3063300T3 (da) Mikropeptider og anvendelse deraf til modulering af genekspression
DK3365684T3 (da) Fremgangsmåde til berigelse af cellefrie nukleosomer
DK3145947T3 (da) Rekombinante mikroorganismer, som er i stand til fiksering af kulstof
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
PL3197493T3 (pl) Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
DK3148584T3 (da) Kombination, der omfatter et glucocorticoid og edo-s101
DK3232780T3 (da) Vandige adjuvans-sammensætninger, der indeholder elektrolyt, sammensætninger, som indeholder et aktivt stof, og anvendelse deraf
DK3212642T3 (da) Amid-substituerede thiazoler som modulatorer af rorgammat
DK3175593T3 (da) Signalering af modulationskonfiguration